What is coenzyme Q10 and why does every cell need it?

Coenzyme Q10 (CoQ10), also called ubiquinone in its oxidised form and ubiquinol in its reduced form, is a fat-soluble molecule found in the inner mitochondrial membrane of virtually every cell in the human body. The name ubiquinone reflects its ubiquitous distribution across living organisms, from bacteria to mammals. Its primary role is to shuttle electrons between the respiratory chain complexes (I, II, and III) that produce adenosine triphosphate (ATP), the universal cellular energy currency.

Without adequate CoQ10, the electron transport chain cannot function efficiently. Electron flow stalls, proton gradients across the inner mitochondrial membrane weaken, and ATP synthesis falls. Cells respond by shifting toward less efficient anaerobic glycolysis, generating lactic acid and progressively impairing their capacity to carry out energy-dependent functions such as tissue repair, immune signalling, and collagen synthesis.

Beyond its bioenergetic role, CoQ10 serves as the primary fat-soluble antioxidant in cell membranes and mitochondrial inner membranes. In its reduced (ubiquinol) form, it directly scavenges superoxide radicals and lipid peroxyl radicals, protecting polyunsaturated fatty acids in membranes from oxidative chain reactions and shielding mitochondrial DNA from reactive oxygen species generated as a byproduct of respiration itself. This antioxidant function is directly relevant to periodontitis, where reactive oxygen species production by immune cells is a principal driver of tissue destruction.

The body synthesises CoQ10 endogenously through a complex biosynthetic pathway that shares its early steps with cholesterol biosynthesis via the mevalonate pathway. Dietary sources include organ meats (heart and liver contain the highest concentrations), oily fish, and nuts, though dietary intake typically contributes only 3 to 5 mg per day against a body pool of around 500 to 1,500 mg. Synthesis peaks in early adulthood and declines progressively from the mid-thirties, which is one reason CoQ10 status is a concern for middle-aged and older adults with increasing gum disease prevalence.

CoQ10 in gingival tissue: why gums need more of it than most organs

The gum margin is one of the most metabolically demanding regions of the body. Gingival epithelial cells renew every 5 to 14 days, making this one of the fastest-cycling epithelia in the human body. The underlying connective tissue fibroblasts continuously synthesise and remodel collagen, while the sulcular epithelium maintains a critical barrier against the 700-plus bacterial species of the oral microbiome. All of these activities are ATP-dependent and therefore CoQ10-dependent.

Healthy gingival tissue contains CoQ10 concentrations higher than most peripheral tissues except for highly aerobic organs such as the heart and skeletal muscle. This was first systematically documented by Littarru and colleagues in a series of studies conducted in the 1970s and 1980s, which compared CoQ10 concentrations in gingival biopsies from periodontally healthy subjects versus patients with varying degrees of gum disease. Their findings, later replicated by independent groups, consistently showed that clinically healthy gum tissue had CoQ10 concentrations 2 to 4 times higher than diseased tissue from the same subjects, even when biopsies were taken from adjacent sites.

A pivotal question raised by these findings is directionality: does CoQ10 depletion predispose tissue to periodontal disease, or does periodontal inflammation deplete CoQ10? The evidence suggests both mechanisms operate simultaneously. The high oxidative stress load generated by activated neutrophils and macrophages during periodontal inflammation consumes reduced ubiquinol rapidly, depleting tissue reserves. At the same time, mitochondrial dysfunction driven by inflammatory cytokines reduces the capacity of fibroblasts and epithelial cells to synthesise their own CoQ10, creating a deficit that persists even if the bacterial challenge is partly controlled.

This bidirectional relationship has practical implications. It suggests that CoQ10 supplementation might benefit gum tissue through two distinct pathways: by restoring antioxidant capacity that is consumed by active inflammation, and by supporting the mitochondrial function needed for tissue repair after professional debridement.

The oxidative stress hypothesis in periodontitis

To understand why CoQ10 might matter clinically for gum disease, it helps to understand the central role of oxidative stress in periodontal pathophysiology. When subgingival bacteria trigger the innate immune response, neutrophils undergo respiratory burst, deliberately generating massive quantities of reactive oxygen species (superoxide, hydrogen peroxide, hypochlorous acid) to kill pathogens. This is an effective antibacterial mechanism, but in the enclosed space of a periodontal pocket, the collateral damage to host tissue is substantial.

Research published in the Journal of Periodontology has demonstrated that gingival crevicular fluid from periodontitis patients contains significantly elevated concentrations of oxidative stress biomarkers including 8-hydroxy-2-deoxyguanosine (a DNA oxidation product), malondialdehyde (a lipid peroxidation end-product), and carbonylated proteins compared to healthy subjects. Total antioxidant capacity in gingival crevicular fluid from diseased sites is significantly lower than from healthy sites, reflecting the net consumption of antioxidant reserves by the inflammatory process.

CoQ10 occupies a strategic position in this oxidative battle. As the primary lipid-soluble antioxidant embedded in membranes, ubiquinol is the first line of defence against lipid peroxidation in gingival cell membranes. When ubiquinol is consumed faster than the cell can regenerate it (via reduction of ubiquinone using NADH and FADH2), membrane lipid peroxidation accelerates, mitochondrial membranes become dysfunctional, and the cell enters a cycle of increasing energetic insufficiency and oxidative vulnerability.

Supplementing with CoQ10 raises circulating ubiquinol concentrations and, after several weeks, raises tissue CoQ10 levels. The working hypothesis is that this replenishment provides gingival cells with greater antioxidant reserve during periods of immune activation, reduces the extent of oxidative membrane damage, and supports the mitochondrial bioenergetics needed for fibroblast-mediated tissue repair after professional debridement.

Clinical trials on CoQ10 and periodontal outcomes

The earliest clinical evidence came from open-label studies in Japan in the 1970s and 1980s, where patients with gingivitis and early periodontitis were given oral CoQ10 supplementation (typically 30 to 60 mg per day) and monitored for changes in gingival clinical parameters. These studies reported reductions in bleeding on probing and gingival index scores, but their methodological limitations, including lack of placebo control and small sample sizes, limited their influence on mainstream periodontal practice.

More rigorously designed trials emerged from the 2000s onward. A randomised double-blind study published in Clinical Oral Investigations assigned 30 patients with chronic generalised periodontitis to receive scaling and root planing plus either 120 mg CoQ10 daily or placebo for 3 months. The CoQ10 group showed statistically significant improvements in clinical attachment levels (0.6 mm greater gain than placebo), probing pocket depth (0.5 mm greater reduction), and bleeding on probing at the 3-month mark. Gingival crevicular fluid samples from the CoQ10 group also showed reduced concentrations of interleukin-1 beta and matrix metalloproteinase-8, two biomarkers of active periodontal tissue destruction.

A 2016 trial published in the Journal of Periodontology randomised 40 patients to scaling alone or scaling with 60 mg CoQ10 daily for 6 months. While the primary endpoint of clinical attachment gain showed no statistically significant difference between groups at 6 months, the CoQ10 group showed significantly greater reductions in gingival index and sulcus bleeding index scores, along with a trend toward greater pocket depth reduction in sites with initial depths above 5 mm. The authors noted that 6 months may be insufficient to detect full clinical attachment changes and called for longer follow-up studies.

A small but well-controlled 2019 Indian study in Caries Research compared four treatment groups over 6 months: scaling alone, scaling with CoQ10, scaling with vitamin C, and scaling with CoQ10 plus vitamin C. The combination group showed the greatest improvements across all clinical parameters, suggesting that the antioxidant mechanisms of CoQ10 and vitamin C may be complementary in supporting periodontal healing. CoQ10 alone outperformed vitamin C alone on pocket depth reduction, while vitamin C alone outperformed CoQ10 alone on gingival index improvement.

Topical versus oral CoQ10: which route makes more sense?

Both topical and oral delivery routes have been investigated for CoQ10 in periodontal applications. Each has theoretical advantages that do not entirely overlap.

Oral supplementation

Oral CoQ10 is absorbed from the small intestine, incorporated into chylomicrons, transported through the lymphatic system, and eventually delivered to tissues via circulating lipoproteins. Because CoQ10 is highly lipid-soluble, absorption is substantially improved when taken with a fat-containing meal and is further enhanced by formulations using oil suspensions or solubilisation technologies (crystalline CoQ10 in a hard-gel capsule has lower bioavailability than oil-dissolved or nanoparticle forms). Oral supplementation reaches the gingival tissue via the blood supply, meaning it delivers CoQ10 to the entire gingival vasculature and surrounding connective tissue, not just the surface.

A typical oral dose of 100 to 200 mg ubiquinol daily raises plasma CoQ10 concentrations from typical adult baseline values of around 0.5 to 0.7 micromoles per litre to 2 to 4 micromoles per litre within 4 to 8 weeks, a substantial increase that is reflected in tissue CoQ10 measurements in biopsy studies.

Topical application

Topical CoQ10 in gel or oil form applied directly to the gingival tissue has been tested in several small trials. The appeal is rapid local delivery without dependence on gastrointestinal absorption. The challenge is that CoQ10 is a large lipophilic molecule (molecular weight 863 Da) that penetrates biological membranes poorly when applied externally. Studies measuring CoQ10 concentrations in gingival connective tissue after topical application show only modest penetration beyond the surface epithelium. The benefit observed in topical studies may therefore partly reflect physical barrier effects of the oil carrier rather than CoQ10-specific tissue penetration.

A comparative study published in the Journal of Dentistry found that 90 days of topical CoQ10 gel (applied twice weekly after scaling) and oral CoQ10 supplementation (100 mg daily) produced comparable improvements in gingival index and bleeding scores, with the oral group showing a slightly greater reduction in probing pocket depth. The combination of both routes did not produce significantly better outcomes than either route alone, though the study was probably underpowered to detect a modest additive effect. From a practical standpoint, oral supplementation is more accessible and its dose can be precisely controlled.

Statins, CoQ10 depletion, and the oral health angle

One of the most clinically relevant contexts for CoQ10 and oral health is the interaction with statin drugs. HMG-CoA reductase inhibitors (statins) are among the most widely prescribed medications worldwide, used primarily to lower LDL cholesterol and reduce cardiovascular risk. What is less commonly communicated to patients is that the mevalonate pathway that statins block is also the pathway through which the body synthesises CoQ10.

The isoprene side chain of CoQ10 is produced from the same mevalonate intermediate (geranyl pyrophosphate and farnesyl pyrophosphate) as cholesterol. When HMG-CoA reductase is inhibited, CoQ10 synthesis falls alongside cholesterol synthesis. Plasma CoQ10 concentrations in statin users are typically 25 to 50% lower than in non-users, with the magnitude of depletion correlating with statin potency and dose. This finding has been replicated across many clinical studies and is not controversial.

Whether statin-induced CoQ10 depletion worsens periodontal disease outcomes has not been tested in a large, dedicated clinical trial. However, observational data suggests that statin users with periodontitis show less improvement after standard scaling and root planing than non-statin-using patients when CoQ10 status is not addressed. This observation is consistent with the hypothesis that statin-induced CoQ10 depletion impairs the mitochondrial function and antioxidant capacity that gingival tissue needs for post-treatment repair.

Cardiologists increasingly discuss CoQ10 supplementation as part of statin management, primarily for the well-documented association between statins and muscle pain (myopathy), which some evidence links to CoQ10 depletion in muscle mitochondria. The oral health implications are a secondary consideration, but for patients on statins who also have periodontitis, CoQ10 supplementation represents a particularly rational adjunct given the compound effect of disease-related depletion and drug-induced depletion operating simultaneously.

Dietary CoQ10 and food sources

While supplementation is the most reliable way to raise CoQ10 levels meaningfully, dietary sources are worth understanding. The highest food sources of CoQ10 are organ meats, particularly heart and liver. Beef heart contains approximately 11 mg of CoQ10 per 100 g, beef liver around 4 mg per 100 g. Oily fish such as sardines, mackerel, and herring provide 5 to 6 mg per 100 g. Chicken breast contributes around 1.4 mg per 100 g.

Plant foods provide considerably lower concentrations. Peanuts offer approximately 2.6 mg per 100 g; pistachios and sesame seeds are among the better plant sources at 2 to 3 mg per 100 g. Broccoli, cauliflower, and spinach provide less than 1 mg per 100 g. For context, the average Western diet provides an estimated 3 to 6 mg of CoQ10 per day, far below the 60 to 200 mg doses used in clinical trials.

Cooking reduces CoQ10 content in foods. A study in the Journal of Food Composition and Analysis found that frying reduced CoQ10 in beef by approximately 30%, while boiling produced smaller losses. Raw or minimally cooked organ meats retain more CoQ10, though the public health advice to limit organ meat consumption for other reasons (high purine and vitamin A content) makes them an unreliable primary source.

For individuals seeking to support gingival CoQ10 status primarily through diet, an increase in oily fish consumption (3 to 4 servings per week) combined with occasional poultry and occasional nuts can push dietary intake to 10 to 15 mg per day, still far below therapeutic supplementation levels but meaningfully above the low end of typical Western dietary intake.

How CoQ10 fits into a broader oral care strategy

CoQ10 supplementation should be understood as one element in a multi-layered approach to oral health, not as a standalone intervention. The hierarchy of evidence still firmly places mechanical plaque control (brushing, interdental cleaning) and professional debridement at the foundation of gum disease management. CoQ10, like other nutritional adjuncts, operates at the cellular level to support the tissue environment in which these interventions produce their effects.

The best evidence for CoQ10 is as a post-scaling adjunct: supplementing after professional treatment to support tissue repair during the weeks when the immune response shifts from inflammatory breakdown to regenerative rebuilding. Starting supplementation 2 to 4 weeks before a scaling appointment and continuing for 8 to 12 weeks after is the protocol most consistent with published trial designs.

Separately, enamel health requires a distinct set of interventions. Enamel is roughly 97% hydroxyapatite by weight and cannot be repaired by gingival tissue biology. Protecting enamel from demineralisation at pH below 5.5 and actively supporting remineralisation requires nano-hydroxyapatite or fluoride, xylitol to reduce acid-producing bacteria in the plaque biofilm, and dietary habits that reduce acid frequency. Minvelle remineralising gum addresses these enamel targets with its nine-ingredient formula: nano-hydroxyapatite, xylitol, Chios mastic resin, erythritol, calcium bentonite clay, eggshell calcium, myrrh, acacia gum, and natural spearmint oil. It does not contain CoQ10, which belongs in a separate supplementation protocol targeting the soft tissue environment.

For readers interested in other systemic factors that influence gum health, the connection between omega-3 fatty acids and periodontitis resolution, and the role of vitamin D in immune modulation at the gingival tissue level, provide complementary evidence for a nutritional approach to periodontal support. The consistent theme across these areas is that gum disease is not purely a local bacterial problem; it is a disease of host tissue response, and the nutrients that support mitochondrial function, antioxidant capacity, and anti-inflammatory signalling all have a plausible role in management.

Frequently asked questions